Qingdao Haier BiomedicalLtd Management
Management criteria checks 3/4
Qingdao Haier BiomedicalLtd's CEO is Zhanjie Liu, appointed in Oct 2005, has a tenure of 19.17 years. directly owns 0.02% of the company’s shares, worth CN¥2.18M. The average tenure of the management team and the board of directors is 5.9 years and 6.3 years respectively.
Key information
Zhanjie Liu
Chief executive officer
CN¥2.4m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 19.2yrs |
| CEO ownership | 0.02% |
| Management average tenure | 5.9yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Does Qingdao Haier BiomedicalLtd (SHSE:688139) Have A Healthy Balance Sheet?
Dec 11
Qingdao Haier BiomedicalLtd's (SHSE:688139) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 06Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Stock Rockets 38% But Many Are Still Ignoring The Company
Oct 03What Is Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Share Price Doing?
Sep 23A Piece Of The Puzzle Missing From Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Share Price
Aug 19Is Qingdao Haier BiomedicalLtd (SHSE:688139) A Risky Investment?
Jun 14Is Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Potentially Undervalued?
May 21Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce
Apr 26Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce
Apr 26CEO
Zhanjie Liu (54 yo)
19.2yrs
Tenure
CN¥2,388,300
Compensation
Dr. Zhanjie Liu is General Manager & Director of Qingdao Haier Biomedical Co., Ltd from October 2005.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 19.2yrs | CN¥2.39m | 0.020% CN¥ 2.2m | |
| Chief Financial Officer | 5.9yrs | CN¥1.39m | 0.0044% CN¥ 492.3k | |
| Deputy General Manager | 3.4yrs | CN¥717.30k | 0.014% CN¥ 1.6m | |
| Deputy GM & Director | 4.8yrs | CN¥824.60k | 0.0044% CN¥ 492.3k | |
| Board Secretary | 6.3yrs | CN¥462.30k | 0.0029% CN¥ 316.7k | |
| Deputy General Manager | 5.9yrs | CN¥794.10k | 0.0044% CN¥ 492.3k | |
| Deputy General Manager | 5.9yrs | CN¥840.90k | 0.0044% CN¥ 492.3k | |
| Deputy General Manager | 2.8yrs | CN¥1.05m | no data | |
| International Human Resources Director | no data | no data | no data | |
| Chief Engineer | 19.2yrs | no data | no data | |
| President of North America | less than a year | no data | no data |
5.9yrs
Average Tenure
48yo
Average Age
Experienced Management: 688139's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 19.2yrs | CN¥2.39m | 0.020% CN¥ 2.2m | |
| Deputy GM & Director | 3.7yrs | CN¥824.60k | 0.0044% CN¥ 492.3k | |
| Director | 6.4yrs | no data | no data | |
| Director | 3.4yrs | no data | no data | |
| Independent Director | 6.3yrs | CN¥150.00k | no data | |
| Independent Director | 6.3yrs | CN¥150.00k | no data | |
| Supervisor | 6.4yrs | no data | no data | |
| Chairman of the Supervisory Board | 1.7yrs | no data | 0.00089% CN¥ 98.9k |
6.3yrs
Average Tenure
52.5yo
Average Age
Experienced Board: 688139's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 21:29 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Qingdao Haier Biomedical Co.,Ltd is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Zhu Chen | Citic Securities Co., Ltd. |
| Shuo Song | Citic Securities Co., Ltd. |